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LETTER TO THE EDITOR
Magnetic Resonance
Imaging Evaluation
of Noninﬂammatory Breast
Cancer with Skin
Involvement After
Neoadjuvant Chemotherapy
TO THE EDITORS:
The tumor response of inﬂammatory breast cancer (IBC)
after neoadjuvant chemotherapy (NAC) evaluated by
magnetic resonance imaging (MRI) has been published in
Annals of Surgical Oncology.
1 We have subsequently
recently noticed a separate category of non-IBC with skin
involvement. Non-IBC with skin involvement is different
from IBC. The clinical course of non-IBC patients with
histologically proven skin involvement showed a far better
disease-free survival and prognosis than IBC.
2 Recent
articles have paid attention to this clinically vague group of
breast cancer, previously categorized as T4 tumor as a
result of pathological involvement of the skin.
2–5 Clini-
cally, non-IBC with skin involvement does not show the
typical skin changes as in the IBC that could be evaluated
visually or by palpation. Therefore, it is recommended that
non-IBC with skin involvement, currently classiﬁed as
T4a–c, should be eliminated from the T4 category.
3 By
means of MRI, we have noted that both IBC and non-IBC
show similar skin enhancements in the tumor-affected
breast. We therefore conducted a comparative study to
investigate the tumor response and the accuracy of MRI in
evaluating these two categories of breast cancer after NAC.
Twelve non-IBC patients (32–52 years old, mean
43 years) with skin involvement were studied and com-
pared with the historical control of previously published 24
IBC patients.
1 All 12 non-IBC patients had stage III to IV
invasive ductal cancer without clinical evidence of IBC.
The skin involvement was diagnosed on the basis of the
ﬁndings of the baseline breast MRI before NAC, which
showed enhancing breast cancer with associated ipsilateral
skin enhancements. The NAC treatment protocol combin-
ing adriamycin and cyclophosphamide (AC) and taxane-
based regimens, MRI examination, and MRI follow-up
studies were the same as the IBC cohort.
1
The non-IBC (1.6–6.1 cm, 3.6 ± 1.3 cm, mean ± SD)
had smaller tumor size than IBC (2.5–16 cm,
6.6 ± 3.2 cm, mean ± SD, P\0.05) and was more likely
to manifest as a mass-type lesion (10 of 12, 83%, vs. 11 of
24, 46%, P\0.05). Despite the different disease entity,
IBC and non-IBC patients showed similar pathological
responses, with 12 IBC patients (12 of 24, 50%) and 6 non-
IBC patients (6 of 12, 50%) achieving pathological com-
plete response (pCR). The clinical complete response was
diagnosed in 67% (16 of 24) of IBC and 50% (6 of 12) of
non-IBC patients (not statistically signiﬁcantly different).
Partial response was found in 29% (7 of 24) of IBC and
50% (6 of 12) of non-IBC patients. The overall accuracy of
MRI was 75% in the IBC group and 84% in the non-IBC
group. The accuracy of MRI in predicting pCR was higher
in non-IBC (5 of 6, 83%) than in IBC (11 of 16, 69%), but
this was not statistically signiﬁcantly different. Twenty
patients (13 IBC and 7 non-IBC patients) with residual
cancer found by either MRI or pathological examination
were included for the size correlation. The Pearson’s cor-
relation coefﬁcient was r = 0.80 in the non-IBC group,
which is slightly higher than r = 0.61 in the IBC group.
All non-IBC cases had tumor size discrepancy between
MRI and pathology of\10 mm (range, 1–9.5 mm), but 9
of 13 IBC had a discrepancy of [10 mm (up to 48 mm),
which was signiﬁcantly higher by Fisher’s exact test
(P\0.005).
In conclusion, IBC and non-IBC with skin enhancement
are two different disease entities, and they showed different
imaging features on MRI. Although IBC was more
aggressive, the response to the NAC combining AC and
taxane-based regimens was not statistically signiﬁcantly
different from that of non-IBC. The accuracy of MRI in
predicting pCR was similar for both cancer types. For
predicting residual tumor size, MRI was more accurate for
non-IBC than IBC with\10 mm of size discrepancy.
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